Our Company

LakeShore Biopharma (Nasdaq:LSB, formerly YS) is a developer and manufacturer of human-used vaccines and other immune products. At present, the main product under sale is freeze-dried human rabies vaccine (Vero cells), and the cumulative sales of this product since its launch have exceeded 80 million units.

The therapeutic PIKA rabies vaccine (Vero cells) jointly developed by the corporate is a major new drug development project of Ministry of Science and Technology of China. The corporate’s pipeline products include: PIKA rabies vaccine (human diploid), PIKA COVID-19 vaccine, PIKA hepatitis B vaccine and etc.

LakeShore Biopharma always adheres to the mission of “To safeguard the human health” and strictly control the quality of corporate’s products. Furthermore, LakeShore Biopharma also adheres to the value of “Rigorous and pragmatic, Striving for perfection, Pursuing excellence, Collaborating for mutual benefit” and safeguards the development of the corporate. The core R&D team members of the corporate have an average vaccine development experience of more than 15 years.